Sun Pharmaceutical Industries Limited
Trial Pipeline
Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency
NCT07385547
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
NCT07282743
Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab
NCT03992729
A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.
NCT06611163
A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients
NCT06425900
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
NCT04991116
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
NCT04314531
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
NCT03997786
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
NCT04314544
Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
NCT03897088
A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)
NCT03528577
Efficacy and Safety Study of SUNPG1623
NCT02980692
Pharmacokinetic and Pharmacodynamic Study of Cyclofem
NCT01699022
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 3 |
| Phase 3 | 6 |
| Phase 4 | 1 |
What the Pipeline for Sun Pharmaceutical Industries Limited Shows
According to the ClinicalTrials.gov registry, Sun Pharmaceutical Industries Limited is linked to 13 US clinical trials across every stage of research activity. Of those, 3 studies are currently recruiting — about 23% of the sponsor's indexed portfolio — and 5 are already marked complete, representing roughly 38% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Sun Pharmaceutical Industries Limited reports 7 late-stage studies (Phase 3 and Phase 4 combined) and 5 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Sun Pharmaceutical Industries Limited is Active Psoriatic Arthritis with 3 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.